Common Contracts
2 similar Immediate Release contracts
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder,Immediate Release • May 28th, 2021
This agent is a novel β3-adrenergic receptor agonist administered once daily, acting selectively on β3 receptors in the bladder, relaxing the bladder to enhance urine collection, and consequently improving the symptoms of urgency, urinary frequency and urge urinary incontinence associated with OAB.
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder,Immediate Release • March 31st, 2021
This agent is a novel β3-adrenergic receptor agonist administered once daily, acting selectively on β3 receptors in the bladder, relaxing the bladder to enhance urine collection, and consequently improving the symptoms of urgency, urinary frequency and urge urinary incontinence associated with OAB.
